Pancreatic Cancer Research

ResearcherCentre National de la Recherche ScientifiqueActive in the last 2 years

Pierre Laurent‐Puig

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8475-5459; OpenAlex author ID A5089818289. Sources: OpenAlex.

Their work

Papers
15 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
70
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: 3 papers · 2020: 2 papers · 2021: 1 paper · 2022: 3 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 15

  1. Prognostic and predictive values of transcriptomic signatures in metastatic pancreatic cancer: A biomarker analysis of three French multicenter prospective ran… Co-author DOI 10.1016/j.canlet.2026.218745↗
  2. The OligoPanc project: an interdisciplinary expert consensus statement on oligometastatic pancreatic cancer. Co-author DOI 10.1016/s1470-2045(25)00714-4↗
  3. Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41598-025-13160-7↗
  4. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41591-023-02790-x↗
  5. BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma. Last author DOI 10.1016/j.clinre.2022.101880↗
  6. Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic adenocarcinoma? Co-author DOI 10.1016/j.dld.2022.01.126↗
  7. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. Last author DOI 10.1038/s41416-021-01624-2↗
  8. Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components. Co-author DOI 10.1158/1078-0432.ccr-21-1907↗
  9. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. Co-author DOI 10.1016/j.ctrv.2020.102028↗
  10. Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-20-0950↗
  11. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1038/s41598-019-53271-6↗
  12. Systemic treatment of pancreatic cancer revisited. Co-author DOI 10.1053/j.seminoncol.2018.12.003↗
  13. hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. Co-author DOI 10.3390/cancers11111808↗
  14. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. Co-author DOI 10.1016/j.ejca.2017.03.022↗
  15. Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker. Co-author DOI 10.1158/1078-0432.ccr-16-0806↗

Closest collaborators

The 25 strongest of 70 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean‐Baptiste Bachet · 12 shared papers, 2017–2026 · strength 1.61
  2. Daniel Pietrasz · 7 shared papers, 2017–2025 · strength 0.92
  3. Jerome F. Cros · 6 shared papers, 2019–2026 · strength 0.81
  4. Shulin Zhao · 5 shared papers, 2020–2026 · strength 0.74
  5. Solène Doat · 4 shared papers, 2017–2025 · strength 0.62
  6. Julien Taı̈eb · 4 shared papers, 2020–2026 · strength 0.61
  7. Rémy Nicolle · 4 shared papers, 2019–2026 · strength 0.57
  8. Louis de Mestier · 4 shared papers, 2019–2026 · strength 0.57
  9. Olivier Caliez · 3 shared papers, 2021–2025 · strength 0.55
  10. Raëf Abdallah · 3 shared papers, 2020–2026 · strength 0.48
  11. Léo Mas · 2 shared papers, 2020–2025 · strength 0.38
  12. Baiyong Shen · 2 shared papers, 2024–2026 · strength 0.37
  13. Laëtitia Dahan · 2 shared papers, 2022–2026 · strength 0.37
  14. Jean–Marc Phelip · 2 shared papers, 2022–2026 · strength 0.37
  15. David Malka · 2 shared papers, 2019–2026 · strength 0.34
  16. Magali Svrcek · 3 shared papers, 2019–2024 · strength 0.33
  17. Mathilde Wagner · 1 shared paper, 2025 · strength 0.27
  18. Isabelle Trouilloud · 1 shared paper, 2026 · strength 0.24
  19. Olivier Bouché · 1 shared paper, 2026 · strength 0.24
  20. Jean‐Luc Van Laethem · 2 shared papers, 2017–2019 · strength 0.15
  21. Thomas Theodor Werner Seufferlein · 2 shared papers, 2017–2019 · strength 0.15
  22. Michel Pierre Ducreux · 2 shared papers, 2017–2019 · strength 0.15
  23. Jiejie Qin · 1 shared paper, 2024 · strength 0.13
  24. Xiaomei Tang · 1 shared paper, 2024 · strength 0.13
  25. Kailian Zheng · 1 shared paper, 2024 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.